The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin
Open accessAbstract
We recently demonstrated that a human recombinant scFv, L19, reacting with the ED‐B domain of fibronectin, a marker of angiogenesis, selectively targets tumoral vasculature in vivo.Using the variable regions of L19, we constructed and expressed a human “small immunoprotein” (SIP) and a complete human IgG1 and performed biodistribution studies in tumor‐bearing mice to compare the blood clearance rate,in vivo stability and performance in tumor targeting of the 3 L19 formats [dimeric scFv (scFv)2, SIP and IgG1]. The accumulation of the different antibody formats in the tumors studied was a consequence of the clearance rate and in vivo stability of the molecules. Using the SIP, the %ID/g in tumors was 2–5 times higher than that of the (scFv)2, reaching a maximum 4–6 hr after injection. By contrast, the accumulation of IgG1 in tumors constantly rose during the experiments. However, due to its slow clearance, the tumor‐blood ratio of the %ID/g after 144 hr was only about 3 compared to a ratio of 10 for the (scFv)2 and 70 for the SIP after the same period of time. The different in vivo behavior of these 3 completely human L19 formats could be exploited for different diagnostic and/or therapeutic purposes, depending on clinical needs and disease. Furthermore, the fact that ED‐B is 100% homologous in human and mouse, which ensures that L19 reacts equally well with the human and the murine antigen, should expedite the transfer of these reagents to clinical trials. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
Bissell, M. J., & Radisky, D. (2001) · Nature Reviews Cancer · doi:10.1038/35094059 · Cited by 2,180
Making antibodies by phage display technology
Winter, G., Griffiths, A. D., Hawkins, R. E., & Hoogenboom, H. R. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002245 · Cited by 1,573
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Signalling through the high-affinity IgE receptor FcεRI
Turner, H., & Kinet, J.-P. (1999) · Nature · doi:10.1038/35037021 · Cited by 739
Jain, R. K., & Baxter, L. T. (1988) · PubMed · Cited by 714
Transport of Molecules, Particles, and Cells in Solid Tumors
Jain, R. K. (1999) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.1.1.241 · Cited by 691
Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat.
Ffrench-Constant, C., Van de Water, L., Dvorak, H. F., & Hynes, R. O. (1989) · The Journal of cell biology · doi:10.1083/jcb.109.2.903 · Cited by 486
Human immune response to multiple injections of murine monoclonal IgG.
Shawler, D. L., Bartholomew, R. M., Smith, L. M., & Dillman, R. O. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.2.1530 · Cited by 422
Design and Use of a Phage Display Library
Pini, A., Viti, F., Santucci, A., Carnemolla, B., Zardi, L., Neri, P., & Neri, D. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.34.21769 · Cited by 422
Self-citationStructure of the Fc fragment of human IgE bound to its high-affinity receptor FcεRIα
Garman, S. C., Wurzburg, B. A., Tarchevskaya, S. S., Kinet, J.-P., & Jardetzky, T. S. (2000) · Nature · doi:10.1038/35018500 · Cited by 355
Milenic, D. E., Yokota, T., Filpula, D. R., Finkelman, M., Dodd, S. W., Wood, J. F., Whitlow, M. D., Snoy, P. J., & Schlom, J. (1991) · PubMed · Cited by 338
Zardi, L., Carnemolla, B., Siri, A., Petersen, T. E., Paolella, G., Sebastio, G., & Baralle, F. E. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02509.x · Cited by 338
Self-citationCarnemolla, B., Balza, E., Siri, A., Zardi, L., Nicotra, M. R., Bigotti, A., & Natali, P. G. (1989) · The Journal of cell biology · doi:10.1083/jcb.108.3.1139 · Cited by 335
Self-citationHu, S., Shively, L., Raubitschek, A. A., Sherman, M. A., Williams, L. E., Wong, J. Y., Shively, J. E., & Wu, A. M. (1996) · PubMed · Cited by 330
The fibronectin isoform containing the ed‐b oncofetal domain: A marker of angiogenesis
Castellani, P., Viale, G., Dorcaratto, A., Nicolo, G., Kaczmarek, J., Querze, G., & Zardi, L. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590507 · Cited by 316
Self-citationSelecting high-affinity binding proteins by monovalent phage display
Lowman, H. B., Bass, S. H., Simpson, N., & Wells, J. A. (1991) · Biochemistry · doi:10.1021/bi00109a004 · Cited by 311
Carnemolla, B., Borsi, L., Balza, E., Castellani, P., Meazza, R., Berndt, A., Ferrini, S., Kosmehl, H., Neri, D., & Zardi, L. (2002) · Blood · doi:10.1182/blood.v99.5.1659 · Cited by 296
Self-citationNeri, D., Carnemolla, B., Nissim, A., Leprini, A., Querzè, G., Balza, E., Pini, A., Tarli, L., Halin, C., Neri, P., et al. (1997) · Nature Biotechnology · doi:10.1038/nbt1197-1271 · Cited by 282
Self-citationEnhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature
Halin, C., Rondini, S., Nilsson, F., Berndt, A., Kosmehl, H., Zardi, L., & Neri, D. (2002) · Nature Biotechnology · doi:10.1038/nbt0302-264 · Cited by 252
Self-citationAdams, G. P., McCartney, J. E., Tai, M.-S., Oppermann, H., Huston, J. S., Stafford, W. F., Bookman, M. A., Fand, I., Houston, L. L., & Weiner, L. M. (1993) · PubMed · Cited by 248
Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.
Adams, G. P., Schier, R., Marshall, K., Wolf, E. J., McCall, A. M., Marks, J. D., & Weiner, L. M. (1998) · PubMed · Cited by 230
Elucidation of the mechanism enabling tumor selective prodrug monotherapy.
Bosslet, K., Straub, R. H., Blumrich, M., Czech, J., Gerken, M., Sperker, B., Kroemer, H. K., Gesson, J., Koch, M. C., & Monneret, C. (1998) · PubMed · Cited by 225
Wu, A. M., Yazaki, P. J., Tsai, S.-W., Nguyen, K., Anderson, A.-L., McCarthy, D. W., Welch, M. J., Shively, J. E., Williams, L. E., Raubitschek, A. A., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150228297 · Cited by 214
Nilsson, F., Kosmehl, H., Zardi, L., & Neri, D. (2001) · PubMed · Cited by 212
Self-citationViti, F., Tarli, L., Giovannoni, L., Zardi, L., & Neri, D. (1999) · PubMed · Cited by 208
Self-citationA High-Affinity Human Antibody That Targets Tumoral Blood Vessels
Tarli, L., Balza, E., Viti, F., Borsi, L., Castellani, P., Berndorff, D., Dinkelborg, L., Neri, D., & Zardi, L. (1999) · Blood · doi:10.1182/blood.v94.1.192.413k22_192_198 · Cited by 206
Self-citationTumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers
Wu, A. M., Chen, W., Raubitschek, A., Williams, L. E., Neumaier, M., Fischer, R., Hu, S.-Z., Odom-Maryon, T., Wong, J. Y. C., & Shively, J. E. (1996) · Immunotechnology · doi:10.1016/1380-2933(95)00027-5 · Cited by 198
Riske, F., Hakimi, J., Mallamaci, M., Griffin, M., Pilson, B., Tobkes, N., Lin, P., Danho, W., Kochan, J., & Chizzonite, R. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99155-6 · Cited by 191
Balza, E., Borsi, L., Allemanni, G., & Zardi, L. (1988) · FEBS Letters · doi:10.1016/0014-5793(88)80580-5 · Cited by 182
Self-citationMonoclonal antibodies in the clinic
Reichert, J. M. (2001) · Nature Biotechnology · doi:10.1038/nbt0901-819 · Cited by 168
Junghans, R. P., Waldmann, T. A., Landolfi, N. F., Avdalovic, N. M., Schneider, W. P., & Queen, C. (1990) · PubMed · Cited by 149
Stephens, S., Emtage, S., Vetterlein, O. M., Chaplin, L. C., Bebbington, C. R., Nesbitt, A. M., Sopwith, M., Athwal, D., Novak, C., & Bodmer, M. (1995) · PubMed Central · Cited by 124
Transforming growth factor‐β regulates the splicing pattern of fibronectin messenger RNA precursor
Borsi, L., Castellani, P., Risso, A. M., Leprini, A., & Zardi, L. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)80664-5 · Cited by 124
Self-citationBirchler, M. T., Viti, F., Zardi, L., Spiess, B. M., & Neri, D. (1999) · Nature Biotechnology · doi:10.1038/13679 · Cited by 112
Self-citationThe use of phage display for the development of tumour targeting agents
Nilsson, F. Y., Tarli, L., Viti, F., & Neri, D. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00068-5 · Cited by 106
Self-citationReduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys
Hakimi, J., Chizzonite, R., Luke, D. R., Familletti, P. C., Bailon, P., Kondas, J. A., Pilson, R., Lin, P., Weber, D. V., & Spence, C. R. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.4.1352 · Cited by 103
Huls, G. A., Heijnen, I., Cuomo, M. E., Koningsberger, J. C., Wiegman, L., Boel, E. C. H., de Vries, A.-R. V. D. V., Loyson, S. A. J., Helfrich, W., Henegouwen, G. P. V. B., et al. (1999) · Nature Biotechnology · doi:10.1038/7023 · Cited by 95
Demartis, S., Tarli, L., Borsi, L., Zardi, L., & Neri, D. (2001) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590100480 · Cited by 90
Self-citationThe Alternative Splicing Pattern of the Tenascin-C Pre-mRNA Is Controlled by the Extracellular pH
Borsi, L., Balza, E., Gaggero, B., Allemanni, G., & Zardi, L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.11.6243 · Cited by 78
Self-citationMammalian cell expression of dimeric small immune proteins (SIP)
Li, E., Pedraza, A., Bestagno, M., Mancardi, S., Sanchez, R., & Burrone, Ó. R. (1997) · Protein Engineering Design and Selection · doi:10.1093/protein/10.6.731 · Cited by 78
Self-citationPini, A., Spreafico, A., Botti, R., et al. (1997) · Journal of Immunological Methods · doi:10.1016/s0022-1759(97)00107-5 · Cited by 22
Affinity reagents against tumour-associated extracellular molecules and newforming vessels
Neri, D., & Zardi, L. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00093-8 · Cited by 17
Self-citation
Cited by
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Arming antibodies: prospects and challenges for immunoconjugates
Wu, A. M., & Senter, P. D. (2005) · Nature Biotechnology · doi:10.1038/nbt1141 · Cited by 1,052
Neri, D., & Bicknell, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1627 · Cited by 600
Self-citationAnti-angiogenesis therapy in cancer: Current challenges and future perspectives
Shojaei, F. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.008 · Cited by 348
Mechanisms of assembly and remodelling of the extracellular matrix
Naba, A. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00767-3 · Cited by 316
Metadata
- Authors
- Borsi, L., Balza, E., Bestagno, M., Castellani, P., Carnemolla, B., Biro, A., Leprini, A., Sepulveda, J., Burrone, O., Neri, D., & Zardi, L.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2002-09-25
- Volume
- 102
- Issue
- 1
- Pages
- 75-85
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2034982045
- Cited by
- 355
- References
- 44
- FWCI
- 8.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.